Collegium Pharmaceutical, Inc. (NASDAQ:COLL) insider Alison B. Fleming sold 4,601 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $17.25, for a total value of $79,367.25. Following the completion of the transaction, the insider now owns 28,513 shares in the company, valued at approximately $491,849.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Collegium Pharmaceutical, Inc. (NASDAQ COLL) traded up $0.98 during trading on Tuesday, reaching $18.58. The company had a trading volume of 1,759,758 shares, compared to its average volume of 480,323. Collegium Pharmaceutical, Inc. has a fifty-two week low of $7.37 and a fifty-two week high of $19.21.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative return on equity of 55.48% and a negative net margin of 110.99%. The business had revenue of $11.95 million for the quarter, compared to the consensus estimate of $5.31 million. During the same quarter in the prior year, the business earned ($1.13) earnings per share. Collegium Pharmaceutical’s revenue for the quarter was up 2814.6% on a year-over-year basis. equities analysts expect that Collegium Pharmaceutical, Inc. will post -2.63 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/21/alison-b-fleming-sells-4601-shares-of-collegium-pharmaceutical-inc-coll-stock.html.

A number of hedge funds have recently modified their holdings of COLL. Bank of New York Mellon Corp raised its holdings in Collegium Pharmaceutical by 6.1% during the 1st quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock valued at $656,000 after acquiring an additional 3,775 shares during the period. American International Group Inc. raised its holdings in Collegium Pharmaceutical by 27.8% during the 1st quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after acquiring an additional 2,163 shares during the period. Vanguard Group Inc. raised its holdings in Collegium Pharmaceutical by 7.8% during the 1st quarter. Vanguard Group Inc. now owns 806,539 shares of the specialty pharmaceutical company’s stock valued at $8,113,000 after acquiring an additional 58,398 shares during the period. Geode Capital Management LLC raised its holdings in Collegium Pharmaceutical by 3.4% during the 1st quarter. Geode Capital Management LLC now owns 146,568 shares of the specialty pharmaceutical company’s stock valued at $1,474,000 after acquiring an additional 4,866 shares during the period. Finally, UBS Group AG raised its holdings in Collegium Pharmaceutical by 283.2% during the 1st quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock valued at $139,000 after acquiring an additional 10,174 shares during the period. 77.23% of the stock is currently owned by institutional investors and hedge funds.

COLL has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research note on Monday, November 13th. Needham & Company LLC reiterated a “buy” rating and issued a $25.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of Collegium Pharmaceutical in a research note on Wednesday, November 8th. Jefferies Group LLC reiterated a “buy” rating and issued a $15.00 price objective on shares of Collegium Pharmaceutical in a research note on Thursday, September 21st. Finally, Piper Jaffray Companies set a $14.00 price objective on Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Tuesday, July 25th. Two investment analysts have rated the stock with a sell rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $19.33.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.